CTOs on the Move

Boston MicroFluidics

www.bostonmicrofluidics.com

 
Boston Microfluidics (BMF) is dedicated to connecting people to their health by increasing access to diagnostic testing for all people. Our technology is a unique combination of elegant sample processing solutions with an intuitive user interface. We strive to streamline current testing systems with devices that perform complex sample processing steps without the need for trained professionals or specialized laboratory equipment. We also seek to simplify diagnostic tests so that they can be used efficiently at the point of care, or even be available for direct sale to consumers. Above all, BMF works to help provide patients with ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Boston MicroFluidics raised $17.5M on 08/27/2019

Similar Companies

Enara Health

Enara Health is building a data-driven platform and network to scale obesity treatment. Based in San Mateo, Calif., and operating since March 2015, Enara Health offers unique hybrid digital and in-person weight loss programs based on precision medicine. By combining mobile technology with health care visits and providing patients with personalized physician-driven medical weight loss programs, Enara Health routinely helps patients lose—and keep off—more than 15% of their baseline weight, which is far greater than the results seen with other m-health interventions.

Kelly Productions Inc

Kelly Productions Inc is a Bel Air, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carolina Medical Electronics

Carolina Medical Electronics is a East Bend, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

InVision Inc.

InVision Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Wave Life Sciences

WAVE Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering exceptional treatment options for patients. Given the unique versatility of its chemistry platform, WAVE`s pipeline will span multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.